Z

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Zanamivir 10mg/mL solution for infusion (Dectova®) SMC 2204	Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: the patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. • the patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or • other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.	Available in line with local guidance for prescribing	178	Feb 2020
Zanubrutinib 80 mg hard capsules (Brukinsa®) SMC2600	As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) SMC restriction: For adults with CLL in whom chemo-immunotherapy is unsuitable.	Available in line with national guidance	195	December 2023
Zanubrutinib 80mg hard capsules (Brukinsa®) SMC2528	As monotherapy for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	191	Nov 2022
Zanubrutinib 80mg hard capsules	As monotherapy for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have	Not available as not recommended for use in NHS	191	Nov 2022

(Brukinsa®) SMC2452 Zanubrutinib hard capsules (Brukinsa®) SMC2671	received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	Scotland	197	Awaiting publication
Ziconotide (Prialt®) (405/07)	Severe, chronic pain in patients who require IT analgesia	Not recommended	73	Oct 2007
Zoledronic acid 5mg (Aclasta®) (535/08)	Osteoporosis in men	Not recommended	86	Jan 2009
Zoledronic acid infusion (Aclasta®) (447/08)	Osteoporosis in post-menopausal women	HOSPITAL ONLY (Medicine, Care of the Elderly)	77	Mar 2008
Zoledronic acid (Zometa®)	Prevention of skeletal related events in breast cancer/multiple myeloma		26 24	2003
Zoledronic acid (Zometa®)	Prevention of skeletal related events in prostate cancer	Not recommended	35 24	2004
Zoledronic acid infusion (Aclasta®)	Paget's disease	HOSPITAL ONLY (Endocrine/Rheumatology Clinics)	62	2006
Zonisamide (Zonegran®) (949/14)	Partial seizures in adolescents and children aged 6 years and above	GPs under the direction of the Paediatric Neurology Clinic	136	Mar/Apr 2014
Zonisamide (Zonegran®) (817/12)	Partial seizures in adults with newly diagnosed epilepsy	Not recommended	121	Nov 2012
Zonisamide (Zonegran®)	Epilepsy	GPs may prescribe under the direction of the Epilepsy Clinic	55	2006

Updated: 17th January 2024

Back to top Back to homepage